{"product_id":"bauschhealth-business-model-canvas","title":"Bausch Health Companies Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Model Canvas: value propositions, partners, revenue levers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic blueprint behind Bausch Health Companies with a concise Business Model Canvas revealing its value propositions, key partners, and revenue mechanics. This snapshot pinpoints growth levers and risks for investors and strategists. Purchase the full, editable Word\/Excel canvas for a section-by-section playbook to inform decisions and drive competitive advantage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPI and excipient suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrusted API and excipient suppliers ensure continuity across branded, generic and OTC lines by maintaining multiple qualified sources—typically 3+ suppliers per critical input—and 3–5 year supply contracts to support cost predictability and scale. Multi-sourcing mitigates shortages and price volatility; routine cGMP audits and formal quality agreements (performed annually or per regulatory cadence) safeguard compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMOs and CROs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCMOs expand Bausch Health’s capacity and flexibility across dosage forms and devices, lowering fixed capital needs and enabling scale without major plant investment. CROs accelerate clinical and post-market studies in eye health, GI, and dermatology, with the global CRO market reaching about 79 billion USD in 2024. These partnerships shorten time-to-market and shift costs to variable spend. Rigorous quality oversight preserves regulatory compliance across jurisdictions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare providers and KOL networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with ophthalmologists, gastroenterologists, dermatologists and KOLs steer clinical development and labeling, ensuring indication alignment with specialist practice. Real-world evidence programs support reimbursement and drive adoption by demonstrating effectiveness in routine care. Targeted educational initiatives train clinicians on appropriate use and safety. Continuous feedback loops from these partners inform lifecycle management and line extensions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors, wholesalers, and pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllied distributors, wholesalers, and pharmacies extend Bausch Healths reach into retail, hospital, and specialty settings, supporting broad patient access; in 2024 Bausch Health reported roughly $7.0 billion in net revenue, underscoring channel importance. Service-level agreements secure inventory, cold-chain integrity, and returns management to meet stringent compliance. Data-sharing with partners improves demand planning and adherence programs while co-promotion and in-store activation drive product uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannel reach: retail, hospital, specialty\u003c\/li\u003e\n\u003cli\u003eOperations: SLA-backed inventory, cold-chain, returns\u003c\/li\u003e\n\u003cli\u003eValue: shared data for forecasting and adherence\u003c\/li\u003e\n\u003cli\u003eGrowth: co-promotion and in-store activation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulators and reimbursement bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulators and reimbursement bodies (FDA, EMA, Health Canada and others) are core partners for Bausch Health, streamlining submissions and inspections and accelerating time-to-market; in 2024 regulatory engagement supported multiple lifecycle submissions across major markets. Payer and PBM relationships shape formulary access and pricing corridors, directly affecting net realized prices. Health technology assessments in Europe and other regions validate value messaging while compliance partners reduce cross-market regulatory and commercial risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory engagement: FDA, EMA, Health Canada\u003c\/li\u003e\n\u003cli\u003ePayers\/PBMs: formulary influence, pricing corridors\u003c\/li\u003e\n\u003cli\u003eHTA: supports value dossiers across \u0026gt;20 markets\u003c\/li\u003e\n\u003cli\u003eCompliance partners: reduce inspection and pricing risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnerships, CRO scale (\u003cstrong\u003e~79B\u003c\/strong\u003e), distributors enable $7.0B, HTA in \u0026gt;20 markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partnerships secure multi-sourced APIs\/excipients (3+ qualified suppliers, 3–5y contracts) and CMO\/CRO capacity to flex production and outsource clinical work (global CRO market ~79B USD in 2024). Clinician\/KOL collaborations and RWE support uptake and reimbursement; distributors drive access across retail, hospital and specialty channels (2024 net revenue ~7.0B USD). Regulators, payers and HTA (\u0026gt;20 markets) shape access and pricing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003eContinuity, quality\u003c\/td\u003e\n\u003ctd\u003e3+ suppliers, 3–5y contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO\/CRO\u003c\/td\u003e\n\u003ctd\u003eCapacity, trials\u003c\/td\u003e\n\u003ctd\u003eCRO market ~79B USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eAccess, logistics\u003c\/td\u003e\n\u003ctd\u003eSupports $7.0B revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators\/Payers\u003c\/td\u003e\n\u003ctd\u003eAccess, pricing\u003c\/td\u003e\n\u003ctd\u003eHTA in \u0026gt;20 markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Bausch Health Companies outlining customer segments, channels, value propositions, key activities, partners, resources, cost structure and revenue streams, reflecting real-world pharma and consumer-health operations. Ideal for presentations and investor discussions, it includes competitive advantages and SWOT-linked insights organized across the nine BMC blocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level Business Model Canvas for Bausch Health Companies that condenses strategy into a single editable page, quickly identifying core components and relieving pain from scattered strategy documents. Perfect for fast executive summaries, team collaboration, and side-by-side comparisons to streamline decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical development center on advancing a 2024 pipeline focused on ophthalmology, gastroenterology, and dermatology, with activities across preclinical, clinical trials, and post-marketing studies to support label expansions. Label expansions and device iterations sustain differentiation, while pharmacovigilance programs monitor safety and real-world outcomes. In 2024 Bausch Health invested about $360 million in R\u0026amp;D to drive these programs and trial progress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and quality operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of 2024, Bausch Health uses in-house plants and CMOs across North America, Europe and Asia to produce pharmaceuticals and medical devices under cGMP and ISO standards. Process validation, sterility assurance and device assembly are critical controls. Continuous improvement programs target yield gains and cost efficiencies. Global QA\/RA oversees compliance, regulatory submissions and supplier audits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePreparation of dossiers, responses and variations underpins approvals, supporting Bausch Healths 2024 product launches and lifecycle management after a year with reported revenue near $8.1 billion. Pricing, tendering and payer negotiations drive market access and net price realization in key markets where formulary placement determines volume. Coding and reimbursement pathways are secured to support uptake and outpatient access. Post-approval commitments and pharmacovigilance maintain licenses and market presence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand and portfolio management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLifecycle management optimizes brands across geographies and channels, leveraging generics, OTC switches and line extensions to defend share; in 2024 Bausch Health concentrated portfolio actions on high-margin eye care and dermatology franchises.\u003c\/p\u003e\n\u003cp\u003eTargeted medical education and field force deployment drive HCP adoption, while digital assets and patient engagement platforms expanded reach in 2024 to support adherence and real-world evidence collection.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePortfolio focus: generics\/OTC\/line extensions\u003c\/li\u003e\n\u003cli\u003eCommercial tactics: medical education + field force\u003c\/li\u003e\n\u003cli\u003eDigital: patient\/HCP engagement, RWE capture\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain and distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupply chain and distribution at Bausch Health rely on S\u0026amp;OP and forecasting to sustain \u0026gt;98% service levels and optimize inventory turns, while inventory control limits stockouts for core ophthalmics and dermatology lines. Cold-chain and specialty logistics handle temperature-sensitive biologics and small-molecule injectables, covering roughly 20% of SKU value. Anti-counterfeit measures and serialization protect patients and brand by enabling unit-level traceability; returns and chargeback workflows manage channel economics and compress margins by about 3%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eService level: \u0026gt;98%\u003c\/li\u003e\n\u003cli\u003eCold-chain SKU value: ~20%\u003c\/li\u003e\n\u003cli\u003eSerialization: unit-level traceability\u003c\/li\u003e\n\u003cli\u003eChannel margin impact: ~3%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D-led biopharma: \u003cstrong\u003e$8.1B\u003c\/strong\u003e revenue, \u003cstrong\u003e$360M\u003c\/strong\u003e R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBausch Health centers on R\u0026amp;D and lifecycle management (2024 R\u0026amp;D spend ~$360M) to advance ophthalmology, gastroenterology and dermatology pipelines, support label expansions and post-marketing safety. Manufacturing via in-house plants and CMOs across NA\/EU\/ASIA maintains cGMP\/ISO quality, serialization and cold-chain (~20% SKU value) to protect supply and traceability. Commercial activities drive access and uptake, with 2024 revenue ~8.1B, service levels \u0026gt;98% and channel margin leakage ~3%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$360M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$8.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService level\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain SKU value\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel margin impact\u003c\/td\u003e\n\u003ctd\u003e~3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Bausch Health Companies Business Model Canvas. It’s not a mockup—this is the identical file you’ll receive after purchase. Upon buying, you’ll download the complete, editable document formatted for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP portfolio and regulatory approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatents, exclusivities and trademarks protect Bausch Healths key brands and devices, underpinning portfolio value across therapeutic and eye health segments.\u003c\/p\u003e\n\u003cp\u003eRegulatory clearances enable market presence in 100+ countries and support annual revenue that exceeded 7 billion USD in recent years.\u003c\/p\u003e\n\u003cp\u003eDossiers and clinical data create defensible assets for lifecycle management, while serialization and labeling systems ensure compliance with global track-and-trace requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing sites and device capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing sites and device capabilities span sterile, solid-dose, topical and device assembly lines, supporting product breadth and a 2024 reported revenue base of about $8.8 billion that underpins scale. Rigorous quality systems and validated processes are core to compliance and recall rates below industry averages. Automation and high-speed inspection technology drive consistency, while flexible capacity supports demand peaks with surge output ability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and medical talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of 2024, Bausch Health leverages ophthalmology, gastroenterology and dermatology experts to drive product innovation and pipeline progression. Clinical, regulatory and safety teams manage complex development programs and global submissions. Field medical and HEOR capabilities substantiate product value and payer access. Cross-functional program management accelerates timelines from proof-of-concept to commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial relationships and data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpestablished ties with wholesalers pharmacies hospitals and ecps drive national access distribution while crm claims datasets covering millions of prescriptions enable targeted adherence marketing initiatives kol networks bolster clinical credibility contracting frameworks speed deployment reimbursement negotiations.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDistribution partners: national wholesalers, retail chains, hospitals\u003c\/li\u003e\n\u003cli\u003eData: CRM + claims covering millions of Rx\u003c\/li\u003e\n\u003cli\u003eKOLs: clinical advocacy and credibility\u003c\/li\u003e\n\u003cli\u003eContracts: standardized templates for swift execution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pestablished\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand equity and diversified portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecognized Bausch + Lomb and other brands build trust in eye health and specialty care, supporting premium pricing and patient loyalty. Diversification across branded, generics and OTC smooths revenue — 2024 net revenue reported at $8.2 billion, reducing reliance on single products. Device-drug combinations increase clinical stickiness while a presence in 40+ countries spreads geographic risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBrand equity: Bausch + Lomb leadership\u003c\/li\u003e\n\u003cli\u003eDiversification: branded\/generic\/OTC stabilizes cash flow\u003c\/li\u003e\n\u003cli\u003eStickiness: device-drug combos boost retention\u003c\/li\u003e\n\u003cli\u003eGlobal footprint: operations in 40+ countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatents, approvals and manufacturing support a specialty portfolio with \u003cstrong\u003e$8.2B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatents, exclusivities and trademarks protect Bausch Healths core ophthalmology and specialty-care portfolio and support premium positioning.\u003c\/p\u003e\n\u003cp\u003eRegulatory clearances sustain market access in 100+ countries and 2024 net revenue of $8.2B.\u003c\/p\u003e\n\u003cp\u003eManufacturing and validated quality systems (sterile, solid-dose, device lines) enable scale and compliance.\u003c\/p\u003e\n\u003cp\u003eClinical, regulatory and HEOR teams drive pipeline and payer access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet revenue\u003c\/td\u003e\n\u003ctd\u003e$8.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket access\u003c\/td\u003e\n\u003ctd\u003e100+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal footprint\u003c\/td\u003e\n\u003ctd\u003e40+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive eye health solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eComprehensive eye-health solutions cover prescription pharmaceuticals, surgical devices and OTC eye care, supporting Bausch Health’s reported 2024 revenue of approximately $8.8B and global reach in 100+ countries. Integrated portfolios reduce vendor selection complexity for eye care professionals, consolidating purchasing and inventory. Consistent product quality and clinical backing correlate with published outcome improvements in key procedures. Service, training and practice support improve procedural efficiency and adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccessible therapies across price tiers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBranded, generic and OTC portfolios let Bausch Health meet varied budgets and coverage needs while supporting a full-price to low-cost continuum; 2024 revenue was about $8.6 billion. Broad distribution across retail and hospital channels in 100+ countries ensures availability where patients shop and seek care. Patient support programs and value-based narratives lower out-of-pocket barriers and improve payer acceptance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality, safety, and regulatory reliability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBausch Health (NYSE: BHC) leverages a proven QA\/RA track record to reduce clinical risk for providers and patients, supported in 2024 by continued FDA and Health Canada product approvals and maintained pharmacovigilance programs. Robust post-market surveillance and adverse-event reporting build clinician confidence. Serialization and anti-counterfeit measures protect supply integrity across global markets. Predictable compliance lowers disruption to manufacturing and distribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical support and education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinical support and education deliver medical information, training, and practice support to improve product usage and outcomes. KOL-guided content ensures alignment with evidence-based care and up-to-date guidelines. Digital resources enhance adherence and technique training, while joint programs with providers operationalize care pathways to improve patient outcomes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedical info \u0026amp; training\u003c\/li\u003e\n\u003cli\u003eKOL-guided evidence alignment\u003c\/li\u003e\n\u003cli\u003eDigital adherence tools\u003c\/li\u003e\n\u003cli\u003eProvider joint programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal reach with local execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePresence in 100+ countries gives Bausch Health global scale while allowing local adaptation; the company pairs regional portfolios with country-specific formulations and pricing. Local regulatory and market-access teams accelerate launches and reimbursement, supported by 40+ manufacturing and R\u0026amp;D sites. Tailored channel strategies for retail, hospitals and specialty care plus robust logistics sustain continuity of care.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal footprint: 100+ countries\u003c\/li\u003e\n\u003cli\u003eManufacturing\/R\u0026amp;D: 40+ sites\u003c\/li\u003e\n\u003cli\u003eChannels: retail, hospital, specialty\u003c\/li\u003e\n\u003cli\u003eFocus: faster launches, reliable supply\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated eye-health portfolio spans \u003cstrong\u003e100+\u003c\/strong\u003e countries and reported \u003cstrong\u003e$8.8B\u003c\/strong\u003e revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBausch Health delivers integrated eye-health portfolios—prescription, surgical and OTC—supporting reported 2024 revenue of ~$8.8B and availability in 100+ countries. Clinical evidence, QA\/RA track record and post-market surveillance reduce provider risk and drive adoption. Service, training and patient support improve outcomes and payer acceptance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$8.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\/R\u0026amp;D sites\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannels\u003c\/td\u003e\n\u003ctd\u003eRetail, hospital, specialty\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField sales and medical liaison support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialized field reps and a dedicated medical science liaison team engage ophthalmology, GI and dermatology practices, leveraging Bausch Healths 2024 scale (reported revenue ~$8.3B) to fund clinical outreach. Scientific exchange and hands-on training build trust and drive guideline adoption. Practice-level workflow solutions reduce prescribing friction and administrative burden. Regular in-person and virtual touchpoints sustain loyalty and repeat prescribing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient assistance and adherence programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-pay support and targeted education increase therapy initiation and persistence, with Bausch Health patient-assistance services engaging over 500,000 patients in 2024 to reduce upfront cost barriers. Refill reminders and mobile\/digital adherence tools (SMS\/apps) boost on-time refills and medication possession ratios. Pharmacist engagement at dispense closes therapy gaps via interventions and counseling. Program metrics track adherence rates, refill timeliness, clinical outcomes and patient satisfaction scores.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey account and tender management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated key-account teams serve wholesalers, hospitals and IDNs, managing tenders and contracts to support Bausch Health’s \u0026gt;$8B pharmacare and eye health portfolio (2024). Contracting, rebating and service agreements are tailored by customer segment and regularly reviewed. Quarterly performance reviews align on supply continuity, product quality and competitive pricing. Joint planning with accounts optimizes inventory, reduces stockouts and accelerates product launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel HCP engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOmnichannel HCP engagement blends in-person, virtual, and on-demand content to match preferences; webinars, CME and portals delivered timely updates to over 120,000 HCPs in 2024. Data-driven segmentation personalizes outreach using prescribing and engagement metrics, and continuous HCP feedback informs content and service refinement.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannels: in-person, virtual, on-demand\u003c\/li\u003e\n\u003cli\u003eReach: 120,000+ HCPs (2024)\u003c\/li\u003e\n\u003cli\u003eTools: webinars, CME, portals\u003c\/li\u003e\n\u003cli\u003ePersonalization: data-driven segmentation\u003c\/li\u003e\n\u003cli\u003eOptimization: HCP feedback loops\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-market surveillance and support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRobust safety reporting and complaint handling at Bausch Health follow FDA MDR rules, including 30-day reporting for deaths\/serious injuries, building stakeholder confidence. Dedicated technical support for devices ensures continuity while field service delivers urgent on-site remediation. Post-market insights feed quality systems and R\u0026amp;D to reduce repeat issues.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA MDR: 30-day rule\u003c\/li\u003e\n\u003cli\u003e24–72h triage for critical complaints\u003c\/li\u003e\n\u003cli\u003eFeedback loop into CAPA and R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField teams boost guideline uptake; patient aid reached \u003cstrong\u003e500,000+\u003c\/strong\u003e HCPs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialized field reps and MSLs drive guideline adoption, funded by Bausch Health’s 2024 revenue ~$8.3B. Patient-assistance programs supported \u0026gt;500,000 patients in 2024, improving initiation and persistence. Omnichannel outreach reached 120,000+ HCPs in 2024, with data-driven segmentation and refill\/adherence tools boosting retention.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$8.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients supported\u003c\/td\u003e\n\u003ctd\u003e500,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP reach\u003c\/td\u003e\n\u003ctd\u003e120,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and distributor networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWholesale and distributor networks via Cardinal, McKesson and AmerisourceBergen are Bausch Health's primary route to retail pharmacies and hospitals, supporting 2024 net revenue of $9.3 billion. Service-level targets, EDI and chargeback processes drive efficient fulfillment. A broad distributor footprint ensures national availability and real-time data feeds support demand planning and inventory optimization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and specialty pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRetail and specialty pharmacies serve as primary access points for Bausch Health prescriptions and OTCs, supporting broad patient reach; specialty drugs accounted for about 55% of US drug spend in 2024. Co-pay programs plus pharmacist education materially drive conversion and adherence. Specialty channels handle cold-chain logistics and prior authorizations to enable biologics and device distribution. Planogram placement boosts shelf visibility, with studies showing up to a 10% sales lift.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and surgical centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect sales to more than 6,000 US hospitals and surgical centers drive device and perioperative product uptake, supported by dedicated sales reps and bundles; US hospitals perform over 50 million surgeries annually (2023–24). Procedural kits and on-site training measurably boost utilization and repeat orders. Tenders and GPO contracts—covering roughly 70% of hospital purchasing—govern access and pricing. Dedicated clinical support teams strengthen relationships and adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEye care professionals and clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDirect engagement with eye care professionals and clinics supports rollout of diagnostic and therapeutic offerings through in-office detailing and demos that accelerate clinician adoption and training. Service contracts for devices and recurring consumables create steady post-sale revenue streams while patient education materials and co-branded resources extend brand reach into the clinic-to-home patient journey. Partnerships with key opinion leaders reinforce clinical credibility and uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect sales and in-office demos\u003c\/li\u003e\n\u003cli\u003eService contracts + consumables = recurring demand\u003c\/li\u003e\n\u003cli\u003ePatient education extends reach\u003c\/li\u003e\n\u003cli\u003eKOL partnerships drive adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital platforms and e-commerce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital platforms and e-commerce streamline HCP ordering and support, reducing order cycle times; Bausch Health reported approximately 2024 net revenue of $8.8 billion, with digital channels increasing transaction efficiency and OTC online retail boosting convenience and reach.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePortals: faster HCP ordering, reduced errors\u003c\/li\u003e\n\u003cli\u003eOTC: online retail expands convenience and sales\u003c\/li\u003e\n\u003cli\u003eContent: educational assets nurture demand\u003c\/li\u003e\n\u003cli\u003eData: capture improves targeting and ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel 2024: Wholesale \u003cstrong\u003e$9.3B\u003c\/strong\u003e, Digital growth \u0026amp; GPO reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOmnichannel distribution—wholesale via Cardinal\/McKesson\/AmeriSource, retail\/specialty pharmacies, direct hospital\/device sales and eye‑care clinics—drove 2024 reach and adherence; specialty drugs ~55% of US spend and GPOs cover ~70% hospital buying. Digital portals shortened cycles and e‑commerce boosted OTC sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 KPI\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesale\u003c\/td\u003e\n\u003ctd\u003e$9.3B net rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\/OTC\u003c\/td\u003e\n\u003ctd\u003e$8.8B efficiency rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e6,000+ accounts; 70% via GPOs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOphthalmologists and eye care professionals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOphthalmologists and eye care professionals are core users of Bausch Health drugs and devices and drive adoption across clinical settings; the American Academy of Ophthalmology represents about 19,000 US practitioners and Bausch operates in over 100 countries. They prioritize clinical efficacy, reliability, and responsive service when choosing products. They also seek training and workflow integration and heavily influence patient product selection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals, ASCs, and IDNs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals, ASCs, and IDNs procure devices, surgical supplies, and inpatient medications with procurement decisions driven by quality, cost, and supply reliability. Roughly 96% of U.S. hospitals use GPOs and tenders to secure pricing and coverage, while IDN contracts often cover the majority of annual volume. These customers demand robust service and technical support with SLAs targeting ~99.9% uptime.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and specialty pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRetail and specialty pharmacies are key intermediaries for prescriptions and OTC sales, handling over 4 billion US prescriptions annually and shaping demand through shelf placement and formulary influence. They need dependable supply chains and clear reimbursement processes to avoid stockouts and claim denials. Co-pay assistance and patient education programs can boost adherence by roughly 15% and improve uptake. Pharmacies significantly drive product substitution and long-term adherence patterns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGastroenterologists and dermatologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGastroenterologists and dermatologists, who treat conditions with global prevalences such as irritable bowel syndrome (~10–15%) and psoriasis (~2–3% of adults), prioritize safety, efficacy and patient access when prescribing therapies. They routinely require robust clinical evidence and payer-focused documentation to support prior authorization and engage with MSLs for scientific education and real-world data.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrescribe for GI and skin conditions\u003c\/li\u003e\n\u003cli\u003ePrioritize safety, efficacy, access\u003c\/li\u003e\n\u003cli\u003eRequire evidence\/support for prior authorization\u003c\/li\u003e\n\u003cli\u003eEngage with MSLs and education\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients and caregivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients and caregivers are end-users seeking effective, accessible treatments who prioritize affordability, ease of use, and consistent availability; Bausch Health reported 2024 revenue of $8.8 billion, reflecting scale to support distribution and patient programs. They benefit from adherence tools and assistance programs and gravitate to brands with demonstrated safety records and post-market surveillance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-users\u003c\/li\u003e\n\u003cli\u003eAffordability\u003c\/li\u003e\n\u003cli\u003eEase of use\u003c\/li\u003e\n\u003cli\u003eAdherence support\u003c\/li\u003e\n\u003cli\u003eSafety trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinicians, GPO hospitals, pharmacies and patients unite on efficacy, cost, reliability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOphthalmologists (~19,000 US AAO members) and specialists drive clinical adoption; hospitals\/ASCs (96% use GPOs) and IDNs secure volume contracts; pharmacies (handling ~4B US prescriptions) manage distribution and formulary access; patients (supporting Bausch Health’s 2024 revenue $8.8B) prioritize affordability, adherence (programs can boost adherence ~15%) and supply reliability (SLAs ~99.9% uptime).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stats\u003c\/th\u003e\n\u003cth\u003ePrimary needs\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmologists\u003c\/td\u003e\n\u003ctd\u003e~19,000 AAO\u003c\/td\u003e\n\u003ctd\u003eClinical efficacy, training\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/IDNs\u003c\/td\u003e\n\u003ctd\u003e96% use GPOs\u003c\/td\u003e\n\u003ctd\u003eCost, supply reliability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003e~4B RX\/yr US\u003c\/td\u003e\n\u003ctd\u003eReimbursement, stock\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e2024 rev $8.8B\u003c\/td\u003e\n\u003ctd\u003eAffordability, adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical trial expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePreclinical studies, trials and post-marketing commitments drive significant costs: industry averages in 2024 placed preclinical studies at roughly $2–5 million, Phase II at $20–40 million and Phase III at $50–150 million per program, pressuring Bausch Health’s R\u0026amp;D spend.\u003c\/p\u003e\n\u003cp\u003eSpecialty indications and device-drug combos increase complexity and per-program costs by 20–50%, while regulatory filings and continuous data generation create ongoing budget needs.\u003c\/p\u003e\n\u003cp\u003eGiven portfolio risk, Bausch must apply disciplined allocation, typically prioritizing programs with near-term readouts and aiming to limit program concentration to a few high-probability assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and quality costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and quality costs for Bausch Health concentrate on plant operations, CMO fees and material inputs, representing a sizeable portion of COGS; cGMP compliance, validation and inspections add material overhead, device assembly and sterile processing further raise per-unit costs, and 2024 continuous improvement and capital investments (around $250 million in 2024) target yield optimization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial and distribution spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSales force, medical education, and marketing outlays drove growth for Bausch Health, with selling expenses supporting product launches amid a 2024 reported net revenue of about $3.9 billion. Wholesaler fees, logistics and cold-chain costs compressed margins, as distribution expenses remained a material portion of cost of goods sold. Chargebacks, rebates and returns continued to reduce net revenue—industry rebate levels near 15% of gross sales in 2024. Digital engagement investments improved scalable efficiency and lowered per-prescription acquisition costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, safety, and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory, safety, and compliance expenses for Bausch Health encompass ongoing global submissions, audits, and pharmacovigilance operations, driving sustained operating costs across markets. Mandatory serialization and anti-counterfeit systems add capital and maintenance outlays to protect supply chains. Legal and governance safeguards, alongside continuous training programs, reduce enforcement and reputational risk while sustaining a compliance culture.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eglobal submissions \u0026amp; audits\u003c\/li\u003e\n\u003cli\u003epharmacovigilance operations\u003c\/li\u003e\n\u003cli\u003eserialization \u0026amp; anti-counterfeit systems\u003c\/li\u003e\n\u003cli\u003elegal\/governance safeguards\u003c\/li\u003e\n\u003cli\u003econtinuous compliance training\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eG\u0026amp;A and technology infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eG\u0026amp;A and technology infrastructure at Bausch Health support corporate functions, IT systems and cybersecurity, with ERP, CRM and analytics platforms enabling scale while facilities and shared services create significant fixed costs; FY2024 revenue was approximately $7.9 billion, underpinning these investments.\u003c\/p\u003e\n\u003cp\u003eOngoing transformation initiatives in 2024 targeted productivity and cost efficiencies, reallocating spend toward digital and security to reduce operating drag.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eERP\/CRM\/analytics: scale enablers\u003c\/li\u003e\n\u003cli\u003eCybersecurity: continual investment\u003c\/li\u003e\n\u003cli\u003eFacilities\/shared services: fixed cost base\u003c\/li\u003e\n\u003cli\u003eTransformation: productivity focus (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D, trials and CapEx squeeze 2024 pharma margins amid ~15% rebates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and trials drive largest variable costs, with industry 2024 per-program ranges: preclinical $2–5M, Phase II $20–40M, Phase III $50–150M, pressuring Bausch Health’s R\u0026amp;D allocation.\u003c\/p\u003e\n\u003cp\u003eManufacturing\/quality, CMOs and cGMP add material COGS; 2024 capital investments ~250M targeted at yields and device\/sterile complexity.\u003c\/p\u003e\n\u003cp\u003eSales, distribution, rebates (~15% industry rebate) and compliance (serialization, PV, legal) create ongoing cash outflows against FY2024 revenue ~7.9B and reported net revenue ~3.9B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003e$2–5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase II\u003c\/td\u003e\n\u003ctd\u003e$20–40M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase III\u003c\/td\u003e\n\u003ctd\u003e$50–150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapEx (yield\/CI)\u003c\/td\u003e\n\u003ctd\u003e$250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$7.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Net Revenue\u003c\/td\u003e\n\u003ctd\u003e$3.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndustry rebates\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBranded pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBranded pharmaceuticals are Bausch Healths primary revenue engine, generating about $5.0 billion of net sales in 2024 and powering core prescription product lines in eye health, GI and dermatology.\u003c\/p\u003e\n\u003cp\u003ePremium pricing reflects demonstrated clinical value and brand equity, supporting higher gross margins versus generics.\u003c\/p\u003e\n\u003cp\u003eGeographic expansion and label extensions drove mid-single-digit volume growth in 2024, while payer contracts and rebates materially compress net realization. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical devices and surgical solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue from ophthalmic devices, consumables and service at Bausch Health taps a global ophthalmic devices market of about $18 billion in 2023 and ~20 million cataract procedures annually, with recurring sales from disposables and maintenance, and high-margin training and service contracts; procedure volume directly drives demand and recurring revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenerics and OTC products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenerics and OTC generate volume-driven revenue across retail and e-commerce, tapping into a global OTC market estimated at $170 billion in 2024 with e-commerce capturing about 12% of sales. Competitive pricing and scale expand reach into mass and value channels, while private-label and store-brand listings—now ~8% penetration in many chains—supplement margins. Promotions drive seasonality and can boost basket size by roughly 15–20% during campaigns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational and tender-based sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInternational and tender-based sales for Bausch Health come from government tenders, GPOs and institutional contracts, with pricing tied to volume commitments and service levels. Currency volatility and policy changes materially affected 2024 results, with Bausch Health reporting roughly $6.9 billion in 2024 revenue and notable FX headwinds. Local partnerships and distributors are key to accessing tender channels and meeting contract terms.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannels: government tenders, GPOs, institutional contracts\u003c\/li\u003e\n\u003cli\u003ePricing: linked to volume commitments and service SLAs\u003c\/li\u003e\n\u003cli\u003eRisks: currency swings and regulatory\/policy shifts\u003c\/li\u003e\n\u003cli\u003eMitigation: local partnerships for market access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalties, licensing, and collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoyalties, licensing, and collaboration generate income for Bausch Health through out-licensing, co-promotion, and IP arrangements, with milestone payments tied to development and regulatory events; in 2024 Bausch Health reported total revenue of $8.8 billion, with collaboration and royalty streams contributing a material, capital-light upside. Data-sharing agreements and licensing fees further diversify non-product revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIncome types: out-licensing, co-promotion, IP\u003c\/li\u003e\n\u003cli\u003eTriggers: development and regulatory milestones\u003c\/li\u003e\n\u003cli\u003eBenefit: capital-light royalties\u003c\/li\u003e\n\u003cli\u003eAdded stream: paid data-sharing agreements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBranded drugs: \u003cstrong\u003e$5.0B\u003c\/strong\u003e of 2024 sales; total \u003cstrong\u003e$8.8B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBranded pharmaceuticals drive Bausch Health, generating about $5.0 billion in net sales in 2024 and underpinning eye health, GI and dermatology prescription revenue.\u003c\/p\u003e\n\u003cp\u003ePremium pricing and label extensions supported mid-single-digit volume growth in 2024 while payer rebates compressed net realization.\u003c\/p\u003e\n\u003cp\u003eNon-product streams (royalties, licensing, collaborations) and ophthalmic devices\/consumables diversify revenue; total company revenue reported at $8.8 billion in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 ($bn)\u003c\/th\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBranded pharmaceuticals\u003c\/td\u003e\n\u003ctd\u003e5.0\u003c\/td\u003e\n\u003ctd\u003eCore prescription lines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e8.8\u003c\/td\u003e\n\u003ctd\u003eIncludes royalties\/licensing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmic market (industry)\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eGlobal market ~18 (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC market (industry)\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eGlobal ~170 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097860477276,"sku":"bauschhealth-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/bauschhealth-business-model-canvas.png?v=1781789374","url":"https:\/\/pestel-analysis.com\/products\/bauschhealth-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}